# A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021

> **NCT00544882** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DR-1021
- **DRUG:** Mircette®
- **DRUG:** Kariva®

## Key facts

- **NCT ID:** NCT00544882
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-31
- **Primary completion:** 2008-03-31
- **Final completion:** 2008-03-31
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2021-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544882, "A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00544882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*